Thema: US28106W1036
EDIT, US28106W1036
gavel-7533906_1920.jpg - Foto: THN
Editas Medicine stock trades at EUR 2.46 before Q3 results
Editas Medicine stock is due to report third-quarter results on November 9. EDIT-401 remains the key clinical focus ahead of human dosing.
ad-hoc-news.de, vor 50 Minuten
EDIT, US28106W1036
Wells Fargo raises target for Editas Medicine stock from ...
Second-quarter revenue was USD 11.89 million versus USD 2.85 million expected. Editas Medicine stock costs EUR 2.34 on October 20, 2026 at 8:20 p.m. CEST.
ad-hoc-news.de, 20.10.26 20:28 Uhr
EDIT, US28106W1036
Editas Medicine stock last stood at EUR 2.15 on October ...
Earnings are scheduled for November 9, 2026. Editas Medicine stock stood at EUR 2.15 on October 16, 2026, 2.38 percent above the Tradegate close.
ad-hoc-news.de, 17.10.26 20:40 Uhr
EDIT, US28106W1036
Editas Medicine stock has November 9 2026 earnings date ...
Second-quarter revenue reached USD 11.89 million, up from USD 2.83 million. Editas Medicine stock costs EUR 2.14 on October 15, 2026.
ad-hoc-news.de, 15.10.26 19:26 Uhr
EDIT, US28106W1036
Editas Medicine stock gained 2.75 percent on October 7 2026 ...
Editas Medicine stock reported USD 11.89 million in Q2 revenue on August 5, 2026, up from USD 3.58 million. Six analysts set a USD 5.80 average target.
ad-hoc-news.de, 08.10.26 03:59 Uhr
EDIT, US28106W1036
Guggenheim upgrades Editas Medicine stock to Buy
Revenue rose to USD 11.89 million from USD 3.58 million in Q2 2026. For Editas Medicine stock, cash reached USD 211.6 million on June 30, 2026.
ad-hoc-news.de, 07.10.26 01:51 Uhr
EDIT, US28106W1036
Editas Medicine stock holds steady as investors weigh latest ...
Editas Medicine stock trades steadily while investors digest recent gene editing developments and look ahead to the company’s next earnings update.
ad-hoc-news.de, 31.08.26 06:56 Uhr
